Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping

In response to the recently published article by Sharma et al, this letter to the editor presents data about the concordance of blood and normal tissue-based evaluation of DPYD genotyping that suggests that pharmacogenetic screening could be contextual to tumor molecular profiling.

Detalles Bibliográficos
Autores principales: Morelli, Cristina, Formica, Vincenzo, Doldo, Elena, Riondino, Silvia, Rofei, Michela, Vergilii, Lorena, Palmieri, Giampiero, Arkenau, Hendrik-Tobias, Roselli, Mario, Orlandi, Augusto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075005/
https://www.ncbi.nlm.nih.gov/pubmed/35325223
http://dx.doi.org/10.1093/oncolo/oyac057
Descripción
Sumario:In response to the recently published article by Sharma et al, this letter to the editor presents data about the concordance of blood and normal tissue-based evaluation of DPYD genotyping that suggests that pharmacogenetic screening could be contextual to tumor molecular profiling.

Ejemplares similares